Skip to main content

Table 1 The dynamic changes of the inflammatory cell populations in pancreatic lesions during pancreatic cancerogenesis (%, Mean ± SEM)

From: Atorvastatin (Lipitor) attenuates the effects of aspirin on pancreatic cancerogenesis and the chemotherapeutic efficacy of gemcitabine on pancreatic cancer by promoting M2 polarized tumor associated macrophages

Cell population

Pancreatic lesions

 

Control (n = 6)

CP (n = 6)

PanIN-1 (n = 5)

PanIN-2 (n = 5)

PanIN-3 (n = 7)

PC (n = 9)

Inflammatory cells

15.50 ± 3.45

27.04 ± 4.75*

30.53 ± 5.57*

34.53 ± 5.45*

45.23 ± 5.40**#&

49.54 ± 6.91**#&@

Th

      
 

15.13 ± 3.34

15.02 ± 3.47

11.02 ± 3.46

10.44 ± 2.30

8.03 ± 2.40*#

8.67 ± 3.11*#

 

2.15 ± 0.57

4.24 ± 0.94*

3.45 ± 1.01*

3.62 ± 0.54*

3.75 ± 2.40*

4.12 ± 0.93*

CTL

12.05 ± 3.55

12.51 ± 3.74

10.12 ± 2.13

7.11 ± 3.40

7.05 ± 2.05*#

6.04 ± 2.55*#

 

1.74 ± 0.25

3.21 ± 0.78*

3.23 ± 1.01*

2.87 ± 0.48*

3.3 ± 1.00*

3.04 ± 0.68*

B cell

      
 

15.07 ± 3.52

16.40 ± 4.22

15.28 ± 3.00

16.24 ± 3.02

14.00 ± 3.25

11.34 ± 3.26

 

2.12 ± 0.26

4.37 ± 1.01*

4.55 ± 0.87*

5.44 ± 0.75*

6.30 ± 1.24*

5.39 ± 1.27*

Granulocyte

35.56 ± 7.22

37.04 ± 5.78

40.52 ± 7.53

47.55 ± 5.07*

55.24 ± 7.30*#

60.24 ± 8.67**##

 

5.27 ± 1.26

10.51 ± 2.33*

13.11 ± 2.46*

15.78 ± 3.61**

25.78 ± 3.89**#&@

31.12 ± 4.97**##&@

Mφ

12.22 ± 3.45

11.55 ± 3.22

14.28 ± 2.77

17.12 ± 4.54#

20.05 ± 4.43*#

22.15 ± 3.65*#

 

1.58 ± 0.42

3.24 ± 0.60*

3.51 ± 0.89*

5.91 ± 1.10**#

9.18 ± 2.16**##&&@

12.11 ± 2.47**##&&@

DC

      
 

7.24 ± 2.25

8.46 ± 3.70

6.74 ± 4.22

10.86 ± 3.36

12.25 ± 4.57

11.23 ± 3.45

 

0.97 ± 0.47

2.15 ± 0.45*

2.04 ± 0.47*

3.56 ± 1.01*

5.52 ± 1.46**#&

5.31 ± 1.89**#&

NK

6.10 ± 1.22

5.84 ± 2.33

5.42 ± 1.65

6.24 ± 2.94

5.54 ± 1.93

4.22 ± 1.58

 

0.88 ± 0.24

1.68 ± 0.67*

1.98 ± 0.49*

2.27 ± 0.75*

2.51 ± 0.68*

2.29 ± 0.84*

NKT

3.01 ± 0.55

3.12 ± 0.97

2.01 ± 0.18

2.02 ± 0.65

2.76 ± 1.15

2.84 ± 1.44

 

0.44 ± 0.21

0.91 ± 0.31

0.67 ± 0.12

0.75 ± 0.09

0.91 ± 0.21

0.83 ± 0.08

MDSC

      
 

5.24 ± 2.16

7.25 ± 2.55

9.25 ± 3.42*

14.14 ± 2.75**#

15.25 ± 3.55**# &

22.34 ± 4.22**##&&@$

 

0.75 ± 0.15

1.79 ± 0.27*

2.75 ± 0.55*

3.64 ± 0.68**#

6.78 ± 1.45**##&&@

10.20 ± 2.07**##&&@@$

M1

      
 

8.54 ± 2.24

8.11 ± 2.78

7.55 ± 2.40

8.67 ± 3.70

9.44 ± 2.12

9.58 ± 2.55

 

1.11 ± 0.27

2.41 ± 0.43*

2.55 ± 0.38*

2.97 ± 0.55*

4.27 ± 1.10**#&

4.68 ± 1.25**#&@

M2

2.72 ± 1.05

2.55 ± 1.17

5.01 ± 1.23*

5.15 ± 1.87*

6.94 ± 2.70*#

11.22 ± 2.77**##&@$

 

0.29 ± 0.05

0.65 ± 0.10*

1.51 ± 0.42**#

2.25 ± 0.84**#

3.14 ± 0.42**##&

5.87 ± 1.28**##&&@$

  1. The proportions of CD45+ inflammatory cells in all cells were compared. And then the proportions of different subpopulations in CD45+inflammatory cells (upper sub-row) and all cells (lower sub-row) were compared,respetively. Th helper T cells, CTL cytotoxic T lymphocyte, Mφ monocyte & macrophage, DC dendritic cells, NK natural killer cells, NKT natural killer T cells, MDSC myeloid derived suppressor cells, M1 M1-polarized tumor associated macrophages, M2 M2-polarized tumor assocaited macrophages. Compared with Control group, * P < 0.05, ** P < 0.01; Compared with CP (chronic pancreatitis), # P < 0.05, ## P <0.01; Compared with PanIN-1 group, & P < 0.05,&& P < 0.01; Compared with PanIN-2, @ P < 0.05, @@ P < 0.01; Compared with PanIN-3, $ P < 0.05, $$ P < 0.01; ANOVA analysis, SNK-q test